Legionnaires' discovery prompts GlaxoSmithKline to idle NC plant

After detecting the bacteria for Legionnaires' disease in a cooling tower, GlaxoSmithKline ($GSK) temporarily closed a manufacturing site in North Carolina. GSK sent employees home while it cleans the tower and investigates. The discovery comes as an outbreak of the infection has resulted in a dozen deaths in New York. More from FiercePharma

Suggested Articles

A few years ago, one of our Fierce editors met a Big Pharma R&D chief for the first time. “You’re the ones with the scary name,” he joked.

Novartis is touting 52-week data for Cosentyx in spondyloarthritis—an indication where Eli Lilly's Taltz recently scored a trailblazing FDA approval.

Bristol Myers Squibb's Zeposia will leverage promising top-line phase 3 data into a possible FDA approval in the lucrative ulcerative colitis market.